Changes in tobacco-related morbidity and mortality in French women: worrying trends.


Journal

European journal of public health
ISSN: 1464-360X
Titre abrégé: Eur J Public Health
Pays: England
ID NLM: 9204966

Informations de publication

Date de publication:
01 04 2020
Historique:
pubmed: 12 11 2019
medline: 25 6 2021
entrez: 12 11 2019
Statut: ppublish

Résumé

The high prevalence of smoking among French women since the 1970s has been reflected over the past decade by a strong impact on the health of women. This paper describes age and gender differences in France of the impact of smoking on morbidity and mortality trends since the 2000s. Smoking prevalence trends were based on estimates from national surveys from 1974 to 2017. Lung cancer incidence were estimated from 2002-12 cancer registry data. Morbidity data for chronic obstructive pulmonary disease (COPD) exacerbation and myocardial infarction were assessed through hospital admissions data, 2002-15. For each disease, number of deaths between 2000 and 2014 came from the national database on medical causes of death. The tobacco-attributable mortality (all causes) was obtained using a population-attributable fraction methodology. The incidence of lung cancer and COPD increased by 72% and 100%, respectively, among women between 2002 and 2015. For myocardial infarction before the age of 65, the incidence increased by 50% between 2002 and 2015 in women vs. 16% in men and the highest increase was observed in women of 45-64-year-olds. Mortality from lung cancer and COPD increased by 71% and 3%, respectively, among women. The estimated number of women who died as a result of smoking has more than doubled between 2000 and 2014 (7% vs. 3% of all deaths). The increase in the prevalence of smoking among women has a major impact on the morbidity and mortality of tobacco-related diseases in women and will continue to increase for a number of years.

Sections du résumé

BACKGROUND
The high prevalence of smoking among French women since the 1970s has been reflected over the past decade by a strong impact on the health of women. This paper describes age and gender differences in France of the impact of smoking on morbidity and mortality trends since the 2000s.
METHODS
Smoking prevalence trends were based on estimates from national surveys from 1974 to 2017. Lung cancer incidence were estimated from 2002-12 cancer registry data. Morbidity data for chronic obstructive pulmonary disease (COPD) exacerbation and myocardial infarction were assessed through hospital admissions data, 2002-15. For each disease, number of deaths between 2000 and 2014 came from the national database on medical causes of death. The tobacco-attributable mortality (all causes) was obtained using a population-attributable fraction methodology.
RESULTS
The incidence of lung cancer and COPD increased by 72% and 100%, respectively, among women between 2002 and 2015. For myocardial infarction before the age of 65, the incidence increased by 50% between 2002 and 2015 in women vs. 16% in men and the highest increase was observed in women of 45-64-year-olds. Mortality from lung cancer and COPD increased by 71% and 3%, respectively, among women. The estimated number of women who died as a result of smoking has more than doubled between 2000 and 2014 (7% vs. 3% of all deaths).
CONCLUSIONS
The increase in the prevalence of smoking among women has a major impact on the morbidity and mortality of tobacco-related diseases in women and will continue to increase for a number of years.

Identifiants

pubmed: 31711145
pii: 5621381
doi: 10.1093/eurpub/ckz171
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

380-385

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.

Auteurs

Valérie Olié (V)

Santé Publique France, The National Public Health Agency, Saint-Maurice, France.

Anne Pasquereau (A)

Santé Publique France, The National Public Health Agency, Saint-Maurice, France.

Frank A G Assogba (FAG)

Santé Publique France, The National Public Health Agency, Saint-Maurice, France.

Pierre Arwidson (P)

Santé Publique France, The National Public Health Agency, Saint-Maurice, France.

Viet Nguyen-Thanh (V)

Santé Publique France, The National Public Health Agency, Saint-Maurice, France.

Edouard Chatignoux (E)

Santé Publique France, The National Public Health Agency, Saint-Maurice, France.

Amélie Gabet (A)

Santé Publique France, The National Public Health Agency, Saint-Maurice, France.

Marie-Christine Delmas (MC)

Santé Publique France, The National Public Health Agency, Saint-Maurice, France.

Christophe Bonaldi (C)

Santé Publique France, The National Public Health Agency, Saint-Maurice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH